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Background: The risk of alcohol-related liver cirrhosis increases with increasing alcohol consump-
tion, but many people with very high intake escape from liver disease. We postulate that susceptibility
to alcoholic cirrhosis has a complex genetic component and propose that this can be dissected through
a large and sufficiently powered genomewide association study (GWAS).
Methods: The GenomALC Consortium comprises researchers from Australia, France, Germany,
Switzerland, United Kingdom, and United States, with a joint aim of exploring the genetic and genomic
basis of alcoholic cirrhosis. For this National Institutes of Health/National Institute on Alcohol Abuse
and Alcoholism funded study, we are recruiting high-risk drinkers who are either cases (with alcoholic
cirrhosis) or controls (drinking comparable amounts over similar time, but free of significant liver dis-
ease). Extensive phenotypic data are obtained using semistructured interviews and patient records, and
blood samples are collected.
Results: We have successfully recruited 859 participants including 538 matched case–control sam-
ples as of September 2014, using study-specific inclusion–exclusion criteria and data collection proto-
cols. Of these, 580 are cases (442 men and 138 women) and 279 are controls (205 men and 74 women).
Duration of excessive drinking was slightly greater in cases than controls and was significantly less in
women than men. Cases had significantly lower lifetime alcohol intake than controls. Both cases and
controls had a high prevalence of reported parental alcohol problems, but cases were significantly more
likely to report that a father with alcohol problems had died from liver disease (odds ratio 2.53, 95%
confidence interval 1.31 to 4.87, p = 0.0055).
Conclusions: Recruitment of participants for a GWAS of alcoholic cirrhosis has proved feasible
across countries with multiple sites. Affected patients often consume less alcohol than unaffected ones,
emphasizing the existence of individual vulnerability factors. Cases are more likely to report liver dis-
ease in a father with alcohol problems than controls, consistent with a potential genetic component to
the risk of alcoholic cirrhosis.
Key Words: Alcoholic Liver Disease, Genomewide Association, Cirrhosis, Genetic Risk Factors,
High-Risk Drinkers.
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BACKGROUND
THE OVERALL RELATIONSHIP between excessivealcohol use and risk of liver damage is well established.
Hepatic steatosis can be found on biopsy in most high-risk
drinkers, but only a minority of these drinkers progress to
alcoholic hepatitis, cirrhosis, or hepatoma. The reasons for
this variation in susceptibility to liver damage, apart from
quantity of alcohol and sex differences (Becker et al., 1996;
Bellentani et al., 1997; Pequignot et al., 1978; Tuyns and
Pequignot, 1984) and perhaps obesity (Iturriaga et al., 1988;
Liu et al., 2010; Naveau et al., 1997), are unknown.
Some evidence for a genetic basis for alcoholic liver
cirrhosis (ALC) comes from early twin studies (Hrubec
and Omenn, 1981) and from the wide interethnic varia-
tion in mortality rates due to ALC (Caetano and Clark,
1998; Stinson et al., 2001). Many nonalcoholic liver dis-
eases (non-ALDs) have been shown to have a genetic
component, and loci affecting risk of hepatitis B or C
infection, primary biliary cirrhosis, drug-associated hepa-
totoxicity, or nonalcoholic fatty liver disease (see http://
www.genome.gov/gwastudies/#searchForm. Accessed May
27, 2014) have been identified by genomewide associa-
tion studies (GWAS). One locus (PNPLA3, rs738409)
discovered through GWAS for nonalcoholic fatty liver
disease was also shown in independent studies to be
associated with ALD severity and was an independent
risk factor for ALC (Nischalke et al., 2011; Seth et al.,
2010; Stickel et al., 2011; Tian et al., 2010; Trepo et al.,
2011, 2012). However, several other candidate gene
approaches to identify risk factors for ALC/ALD remain
inconclusive (Stickel and Hampe, 2012). Moreover, no
genomewide association approaches have yet been pur-
sued to identify loci contributing to risk for alcoholic
cirrhosis.
We have initiated a multicenter international program to
collect DNA samples from thousands of high-risk drinkers,
half of whom will have alcoholic cirrhosis (cases) while the
other half will have no clinical evidence of significant liver
disease (controls). We will conduct a GWAS by genotyping
and comparing allele frequencies for single-nucleotide poly-
morphisms (SNPs) between the 2 groups to identify genetic
factors that predispose drinkers to, or protect them against,
alcoholic cirrhosis. We postulate that identification of genetic
risk factors that predispose some drinkers to develop ALC
may lead to an improved understanding of how alcohol dam-
ages the liver, strategies to prevent liver disease, and new
treatment modalities.
This report summarizes our approach to establish the first
international database of clinical and genetic data and bio-
logical samples from heavy drinkers with and without liver
cirrhosis and provides descriptive data for the first 859 study
participants from our data collection (recruited up to the end
of September 2014).
MATERIALS ANDMETHODS
Study Design
This case–control study is conducted by the international Geno-
mALC Consortium comprising researchers from Australia, France,
Germany, Switzerland, the United Kingdom, and the United States
(Fig. 1). This multicenter study aims to recruit equal numbers of
cases and controls, with approval from respective sites’ institutional
review boards, informed consent of the participants, and following
National Institutes of Health (NIH) guidelines. All international
sites began active recruitment of participants in September 2012
with an aim to collect a total of 5,000 participants, recruited both
prospectively and from existing repositories of participating centers.
An important task in such association studies is a clear definition
of the cases and controls. For ethical reasons, liver biopsy in alco-
holics without clinical or biochemical evidence of liver disease is not
justifiable. Consequently, we have adopted the approach used by
prior genetic studies in ALD, namely to select control patients who
have a history of heavy drinking but with normal liver tests and no
current or prior evidence of cirrhosis nor, if liver biopsy has been
performed, of any liver fibrosis. A control group of high-risk drink-
ers, rather than a control group from the general population, is nec-
essary to clearly distinguish the genetics of alcoholic cirrhosis from
the genetics of alcohol dependence.
Recruitment and Inclusion/Exclusion Criteria
Patients presenting to liver or alcohol treatment clinics who
fulfill the recruitment criteria are invited to enroll in the study.
Controls
(without cirrhosis)
N = 2500
Cases
(with liver cirrhosis)
N = 2500
• Identification of genetic risk factors for ALC
• Largest database of DNA and clinical  
information from patients with ALC
• Data & DNA resource for future research
Drinkers: 50-80g/day for 10 years or more
Participant recruitment from six countries
Australia France Germany Switzerland UK USA
Consent, Interview, Clinical 
data collection, Blood draw
DNA extraction, Genotyping 
(SNP-GWAS, Sequencing)
Data analysis, SNP profiling
Yr 1
Yr 2
Yr 3
Yr 4
Yr 5
Fig. 1. GenomALCConsortiumworkflow to conduct genomewide asso-
ciation study (GWAS) for alcoholic cirrhosis. ALC, alcoholic liver cirrhosis;
SNP, single-nucleotide polymorphism.
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Consenting participants are given a unique de-identified study-
specific number as the only identifier used for tracking samples.
De-identified study-specific numbers are centrally generated as
barcode labels and human readable codes and distributed to
participating sites. The study inclusion–exclusion criteria require
that participants must have had alcohol consumption averaging
at least 80 g per day (for men) or 50 g per day (for women),
for at least 10 years. This criterion is based on epidemiological
evidence of the alcohol–cirrhosis relationship. The cutoff was
set at a relatively high level so as to minimize the chance that
cirrhosis was caused by factors other than alcohol. However, it
is not essential for either cases or controls to meet the Diag-
nostic and Statistical Manual of Mental Disorders (DSM) crite-
ria for alcohol dependence (American Psychiatric Association,
1994). In practice, most will do so, but the key criterion is pro-
longed high-risk alcohol intake rather than dependence per se.
Cases have evidence of cirrhosis as per clinical signs and/or
noninvasive transient elastography (Fibroscan; Echosens, Paris)
and/or histopathology by biopsy, with exclusion of hepatitis B
or C, autoimmune liver disease, hemochromatosis, Wilson’s dis-
ease, and liver transplantation for liver disease other than
ALC. Unequivocal evidence of cirrhosis is defined as imaging
results (sonography, computed tomography, magnetic resonance
imaging) compatible with cirrhosis together with detectable asci-
tes by imaging or paracentesis and/or grade 2 or higher spon-
taneous hepatic encephalopathy and/or moderate or large
esophageal varices on upper gastrointestinal endoscopy. Histo-
logical cirrhosis on biopsy is defined as Metavir fibrosis stage
F4 or Ishak fibrosis stage 5 or 6. Controls have normal results
for aspartate aminotransferase, alanine aminotransferase, total
bilirubin, albumin, platelet count, and international normalized
ratio while actively drinking or within 7 days of stopping, the
most recent episode of heavy alcohol use, and no evidence of
liver disease (clinical and/or Fibroscan and/or histopathology
showing F1, F2, F3, or F4 fibrosis, pericellular/intrasinusoidal
fibrosis, perivenular fibrosis, or alcoholic hepatitis). HIV infec-
tion is an exclusion criterion for both cases and controls.
Instruments for Conducting the Study
We have developed standard operating procedures to maintain
uniformity across sites for the operational and administrative steps
to be followed during the study. These are distributed through the
Consortium’s website www.genomalc.org. The website provides an
overview of the study, which is open to all, and will provide a means
for public dissemination of research outcomes as these emerge. The
protocols and resources are restricted to researchers involved in the
study. A data entry spreadsheet designed for the study records data
collected through the questionnaires. The data entry design has built
in formulae and conditional formatting that take into account the
units and normal ranges of biochemical data that vary across the 6
countries and converts these into standard units. It also has built in
warnings if data are out of range, incorrect, or misclassified. This
design also assists in extracting data in a format that can be used for
matching of cases and controls for age, gender, and ethnicity, and
for extraction for data analysis (e.g., SPSS). To ensure that case and
control groups overall are comparable for age and gender, we have
adopted a stringent strategy to match cases to controls at the time
of collection. For this, a semi-automated Excel-based algorithm is
designed to match each case with a control for age, gender, and eth-
nicity. The system can match hundreds of controls to cases simulta-
neously, both site by site and globally. Participants with
mismatched ethnicity are excluded from matching. Controls are
matched for age within 3 to +5 years of cases. We have chosen to
match the age at diagnosis for the cases to the age at study participa-
tion of controls.
Data and Sample Collection
Data collection uses a combination of face-to-face interview
and medical-record sources. Data are collected regarding demo-
graphics, ancestry, alcohol and tobacco history, education, clini-
cal symptoms, blood biochemistry, severity and date of
diagnosis of cirrhosis, medication, drug use, anthropometrics,
and other potential covariates that might affect development of
cirrhosis (Table S1). We have set up a central database at the
QIMR Berghofer Medical Research Institute (QIMR) in Bris-
bane, Australia, using existing facilities for managing epidemio-
logical data with appropriate data security (backup, encryption,
and access control). Data from the collection centers are
uploaded after local entry and stored at QIMR. Each data file
is checked by the site PI followed by the study coordinator to
control quality of data received. Tools to review enrollment
and matching of enrolled participants (case to control, male
and female, age) are used to monitor recruitment monthly.
Blood is drawn and stored appropriately in specific tubes for
DNA (essential), RNA, and serum/plasma (optional) extraction.
All prospectively collected blood samples for DNA are shipped
frozen to our laboratory in Indiana, USA, for central processing.
DNA isolation is centralized to maintain the quality standard.
Nanodrop measurements for 260/280 optical density ratio and
concentration are used to determine the quality of DNA. If quality
is not up to specification, DNA isolation is repeated from the
remaining blood sample.
Sample Numbers, Power, and Effect Size
To determine the optimum case to control proportions for
this study, we used Genetic Power Calculator (http://pngu.mgh.
harvard.edu/~purcell/gpc/). The best power for any genotypic
relative risk was obtained when the number of cases and con-
trols were equal, reaching 86% (at a per-allele relative risk of
1.3) with 2,500 cases and 2,500 controls (Table S2, Model 1).
Assuming a loss of up to 15% of the samples due to a variety
of reasons (insufficient DNA quality, unavailability of pheno-
typic data, inappropriate matching with controls, etc.), Model 2
(Table S2) shows that ~72% power is retained to identify SNPs
associated with a per-allele relative risk of 1.3. Our aim of
obtaining a total of 5,000 participants, more than the minimum
requirement of N = 4,937 for 80% power (Table S2), provides
sufficient power to opt for genomewide SNP genotyping. We
will prospectively recruit from the participating multinational
sites 1,250 cases and 1,250 control samples during the first
4 years. We also have access to >2,500 retrospective samples
from high-risk drinkers with or without liver disease from pre-
vious studies which we plan to include in the genotyping.
Once all samples have been collected, which is expected to be in
2016, we will utilize the most appropriate genomewide chip avail-
able to genotype the study population. We propose to undertake
this in partnership with the Centre for Inherited Disease Research,
a NIH-funded central facility that provides genotyping for investi-
gators seeking to identify genes that contribute to human disease.
Clinical Data Analysis
The preliminary analysis presented on the first 859 subjects is to
test the feasibility of our study design for recruitment across multi-
ple centers internationally and to determine whether our recruit-
ment strategy and criteria for defining cases and controls is valid.
Statistical tests were performed using SPSS, version 22 (IBM Cor-
poration, Armonk, NY). Because our main aim at this stage is to
demonstrate equivalence between cases and controls, reported p-
values are not adjusted for multiple comparisons.
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RESULTS
Recruitment, Demographics, Alcohol Data, and DNAQuality
Initial screening identified 943 potential subjects (cases or
controls) of which 16 did not meet the alcohol intake criteria,
and another 25 have incomplete data. These are excluded
from current analysis. The frequency distribution on the
cohort profile is on the remaining 902 including n = 43 with
non-Caucasian ancestry (Fig. S1A). The clinical analysis is
performed only on those eligible for matching, n = 859
(902  43). So far, we have recruited more cases (N = 580)
than controls (N = 279) and more males (N = 647) than
females (N = 212). However, we have been successful in
obtaining a similar ratio of males to females in the 2 groups
(73% men among controls, 76% men among the cases).
Clinical evidence of cirrhosis in cases was verified by the
presence of ascites and/or grade 2 or higher hepatic encepha-
lopathy and/or moderate to large esophageal varices. Our
data show that 76% of the cases had ascites, 37% grade 2 or
higher hepatic encephalopathy, and 57% esophageal varices.
Eleven percent of cases had been diagnosed with hepatoma
(in addition to cirrhosis), and 95% had at least 1 of these
complications. This cohort is thus largely comprised of
advanced liver disease with complications. The cohort pre-
dominantly consists of European Caucasian (>95%) partici-
pants, and in this cohort, approximately 63% (538/859)
could be matched for age, gender, and ethnicity, identifying
269 case–control pairs (Fig. S1A).
DNA extracted from ~53% of the samples (n = 455) has
resulted in good quality as shown by OD260/280 ratio and
concentration (Fig. S1B). Approximately 1% of samples (5
of 455 extractions) that needed repeat processing also
resulted in desired quality and concentration appropriate for
genotyping for all samples tested so far. The distribution of
DNA concentration across samples is shown in Fig. S1C.
Lifetime Alcohol Intake in Cases and Controls
Quantitative data on duration and amount of excessive
drinking, allowing estimation of lifetime alcohol intake, were
available for 895 of the participants. Cases and controls
reported very similar duration of excessive drinking. For
men, the mean duration was 25.4 years in the cases and
23.7 years in the controls and for women 19.4 and 18.7 years,
respectively. The controls reported more alcohol intake per
day than cases; the means for men were 213 g per day for
cases and 256 g per day for controls and for women
158 g per day for cases and 218 g per day for controls. Male
cases had consumed a mean lifetime amount of 1,965 kg of
ethanol (EtOH, 1,073 kg in women), and controls had con-
sumed significantly more (mean lifetime amount of 2,212 kg
of EtOH for men and 1,495 kg in women). Details of mean
and median amounts are shown in Table 1, and the cumula-
tive frequency distributions for male and female cases and
controls are shown for duration (Fig. S2A), estimated alco-
hol intake per day (Fig. S2B), and estimated lifetime alcohol
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intake (Fig. S2C). Past-year alcohol intake, estimated from
the frequency and quantity questions in the Alcohol Use Dis-
orders Identification Test (AUDIT), and the overall AUDIT
score were both significantly lower in the cases than controls
(Table 1). Case–control comparison by country, for grams of
EtOH per day and lifetime kg of EtOH, confirms that
amount of alcohol consumed per day and over lifetime was
consistently higher for controls than cases at all recruitment
countries (Fig. S3).
History of Alcohol Problems and Liver Disease in Parents
We asked participants about alcohol problems in their
father or mother and whether their father or mother died
from liver disease if they did have alcohol problems. The
prevalence of alcohol problems was higher for the fathers
than mothers; about half the participants reported problems
in fathers and about a fifth reported problems in mothers.
The prevalence of both paternal- and maternal-reported
alcohol problems was slightly greater in the controls
(Table 2A).
Taking only subjects who reported alcohol problems in a
parent (because only those parents were at risk of alcoholic
cirrhosis), the risk of cirrhosis is significantly (p = 0.0055)
increased if a subject’s father died of liver disease, but not
significantly if their mothers died from liver disease (perhaps
due to lower numbers; Table 2B). However, the trends were
in the same direction, with higher rates of reported liver
deaths in both the fathers and the mothers of cases. Logistic
regression, adjusted for sex, age at diagnosis, and lifetime
alcohol intake, gave similar results (p = 0.0042 for father
having died of liver disease if he had an alcohol problem,
p = 0.626 for mother having died of liver disease if she had
an alcohol problem; Table 2C).
DISCUSSION
While genomewide screening has been applied for numer-
ous diseases including chronic liver diseases, such approach
has been lacking for ALD until now. ALC has an enormous
impact on the burden of liver disease; therefore, knowing its
genetic background would be extremely valuable for both
practical screening considerations and research purposes. As
ALC is a disease linked to xenobiotic exposure, it is possible
that relatively strong single polymorphism effects will be
found, as in smaller studies where large and highly significant
effects have been detected for single polymorphisms (Daly
et al., 2009; Newton-Cheh et al., 2009). There are also exam-
ples where suggestive GWAS has resulted in a list of possibil-
ities for further studies (Purcell et al., 2009). Our
Table 2. Family History of Alcohol Problems and Death from Liver Disease
(A) Prevalence of reported parental alcohol problems by case–control status
Yes No Percent yes
p-Value
Odds ratio
95%CI
Did father have alcohol problems?
Cases 239 312 43.4 p = 0.061
Odds ratio 1.33
95% CI 0.99 to 1.78
Controls 134 132 50.4
Did mother have alcohol problems?
Cases 88 469 15.8 p = 0.0078
Odds ratio 1.63
95% CI 1.14 to 2.34
Controls 64 209 23.4
(B) Prevalence of reported parental death from liver disease, in parents with alcohol problems, by case–control status
Yes No Percent yes
p-Value
Odds ratio
95%CI
Did father die of liver disease?
Cases 52 160 24.5 p = 0.0055
Odds ratio 2.53
95% CI 1.31 to 4.87
Controls 13 101 11.4
Did mother die of liver disease?
Cases 14 62 18.4 p = 0.653
Odds ratio 1.25
95% CI 0.50 to 3.14
Controls 9 50 15.3
(C) Logistic regression: case–control status by whether father or mother died of alcoholic liver disease (in subjects reporting that their father or mother,
respectively, had alcohol problems); adjusted for age, sex, and log-transformed lifetime alcohol intake
B SE (B) p Exp (B)
Father died of liver disease 0.983 0.343 0.0042 2.67
Mother died of liver disease 0.231 0.474 0.626 0.79
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GenomALC study design and approach have strong poten-
tial to generate new information on the genetic architecture
and the heritability of ALC. Hence, conducting a GWAS in
ALC seems timely and necessary.
To address this task, the GenomALC Consortium was
established whose aims, design, and progress are described,
and information provided on alcohol use in the first 859 case
and control subjects enrolled to date. Several points emerge
from this preliminary analysis. The cases were diagnosed
with cirrhosis at a mean age of 52.6 for men and 49.7 for
women, after a mean of 25.4 and 19.4 years of excessive
drinking. However, the ranges were wide: 26 to 73 years for
age and 10 to 57 years for excessive drinking. Moreover,
there was a wide range of lifetime alcohol intake among the
cases, suggesting variation in vulnerability. Admittedly, these
estimates of lifetime intake are retrospective and may have
substantial error, but the differences are striking, ranging 7-
fold from 511 kg (10th centile) to 3,500 kg (90th centile) of
EtOH intake to achieve cirrhosis. The data on lifetime alco-
hol intake in cases and controls across all recruitment sites
confirm that it is perfectly possible to progress to cirrhosis
after a lifetime alcohol intake, which is lower than that
reported by control subjects without cirrhosis.
The cases also had lower past-year alcohol intake and
AUDIT scores compared to the control group, which may
be due to their recognition of the implications of contin-
uing drinking for their liver disease. It could also be due to
the inclusion of currently abstinent drinkers recruited under
transplant settings in the case, but not in the control group.
However, this does not affect our conclusion about lifetime
alcohol consumption being no greater in the cases than in
matched controls. Overall, our results strengthen the case
for the existence of individual susceptibility factors in
ALD.
It is possible that our case–control definition and recruit-
ment instruments, in the absence of liver biopsy, may result
in inclusion of some patients with fibrosis as controls; how-
ever, controls are highly unlikely to have cirrhosis. As cases
are matched for age at diagnosis with controls, it is unlikely
that factors (such as gene polymorphisms) that contribute
significantly to the development of cirrhosis will be obscured
by inclusion of some patients with fibrosis in the control
group. We also acknowledge that it is possible, but uncom-
mon, to develop ALC with alcohol intakes <80 g per day
(men) and <50 g per day (women). Such patients would be
at the extreme of individual risk, but do not meet the recruit-
ment criteria for this study. We set these entry criteria to be
confident that cases included in the study did indeed have
alcohol-induced cirrhosis. The attribution of alcohol as the
etiology for cirrhosis is less clear for individual cases at lower
levels of consumption.
The association between case–control status and family
history of an alcoholic parent dying from liver disease is a
novel and potentially important finding. Although the most
likely interpretation is that this is due to genetic transmission
of risk, effects of shared environment or recall bias cannot be
excluded. At this stage, the effect is not statistically signifi-
cant for maternal history. This result adds to the justification
for performing a GWAS, assuming it is confirmed with the
increased numbers as recruitment proceeds. We also found
that slightly more parental alcohol problems were reported
by controls than cases. For both groups, the rate was above
that expected for the general population (Grant, 1997; Heath
et al., 1997), consistent with previous studies showing famil-
ial aggregation and significant heritability of alcohol
problems.
In conclusion, we report that through the establish-
ment of our international GenomALC Consortium, it
has proven feasible to recruit and collect data and sam-
ples from chronic high-risk drinkers for our overall aim
to identify genetic loci for risk of ALC. In future, identi-
fication of relevant loci is expected to give insight into
the mechanisms of ALD and may (depending on the
size of allelic effects) allow identification of at least some
high-risk people. In the meantime, our recruitment of a
substantial number of people allows us to assess disease
associations and potential risk factors using self-report,
clinical, and laboratory data. Analysis of these aspects
on the entire collection including this cohort is antici-
pated once recruitment is complete. A significant benefit
of this study is the establishment of a central database
of clinical characteristics and a biorepository of DNA
from a large cohort of heavy drinkers, with consequent
opportunities for future collaborations and research.
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